ECSP014068A - Procedimiento para regular la angiogenesis utilizando proteina ryk - Google Patents

Procedimiento para regular la angiogenesis utilizando proteina ryk

Info

Publication number
ECSP014068A
ECSP014068A EC2001004068A ECSP014068A ECSP014068A EC SP014068 A ECSP014068 A EC SP014068A EC 2001004068 A EC2001004068 A EC 2001004068A EC SP014068 A ECSP014068 A EC SP014068A EC SP014068 A ECSP014068 A EC SP014068A
Authority
EC
Ecuador
Prior art keywords
ryk
angiogenesis
diseases
procedure
proteins
Prior art date
Application number
EC2001004068A
Other languages
English (en)
Spanish (es)
Inventor
Alya Zolotorev
Nathalie A Dubois-Stringfellow
Steve Roczniak
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of ECSP014068A publication Critical patent/ECSP014068A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EC2001004068A 2000-05-10 2001-05-09 Procedimiento para regular la angiogenesis utilizando proteina ryk ECSP014068A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
ECSP014068A true ECSP014068A (es) 2002-02-25

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004068A ECSP014068A (es) 2000-05-10 2001-05-09 Procedimiento para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (https=)
JP (1) JP2004527206A (https=)
AR (1) AR028424A1 (https=)
AU (1) AU2001261343A1 (https=)
CA (1) CA2408349A1 (https=)
CO (1) CO5300464A1 (https=)
DO (1) DOP2001000164A (https=)
EC (1) ECSP014068A (https=)
GT (1) GT200100079A (https=)
PE (1) PE20011218A1 (https=)
SV (1) SV2002000442A (https=)
UY (1) UY26696A1 (https=)
WO (1) WO2001085789A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
CA3229528A1 (en) * 2021-08-18 2023-02-23 The Regents Of The University Of California Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
NZ328371A (en) * 1994-12-23 1999-05-28 Ludwig Inst Cancer Res Method of detecting a ligand capable of binding the receptor protein neuroepithelial tyrosine kinase (nyk) and its use in therapeutic compositions
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
CA2348835A1 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Also Published As

Publication number Publication date
DOP2001000164A (es) 2002-05-15
EP1287121A2 (en) 2003-03-05
GT200100079A (es) 2001-12-31
SV2002000442A (es) 2002-07-03
CA2408349A1 (en) 2001-11-15
UY26696A1 (es) 2001-12-28
CO5300464A1 (es) 2003-07-31
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
AR028424A1 (es) 2003-05-07
WO2001085789A3 (en) 2002-05-16
WO2001085789A2 (en) 2001-11-15
PE20011218A1 (es) 2002-02-01

Similar Documents

Publication Publication Date Title
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
IL117645A (en) Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
DE59811158D1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
ES2180629T3 (es) Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.
AR046993A1 (es) Derivados de quinazolina
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
DK1343472T3 (da) Thixotropisk næsespray
ECSP014068A (es) Procedimiento para regular la angiogenesis utilizando proteina ryk
ES2186576A1 (es) Acido 2-hidroxioleico para utilizar como medicamento.
MX9701996A (es) Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno.
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
DE60107444D1 (de) Verwendung einer pollenextrakt-enthaltenden verbindung zur behandlung von ödemen
ATE373482T1 (de) Pharmazeutische zusammensetzung zur lokalen behandlung von hauterkrankungen und hautwunden
DOP2001000141A (es) Proteina actuando como un modulador angiogenico
ATE302000T1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
SV2002000362A (es) Proteinas que tienen una actividad moduladora de angiogenesis ref.msb-7265-sv
DE60222633D1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
AR011907A1 (es) UTILIZACIoN DEL ACIDO 4-(2,2-DIMETILPROPANOL)BUTANOICO (PIVAGABIN)PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE FORMAS DE ANSIEDADDEPRESIVA.
WO2001074852A3 (en) Protein having activity as an angiogenesis modulator
MX2024014811A (es) Composiciones de menaquinol pegilado y metodos de tratamiento